{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:10:44Z","timestamp":1782853844079,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020192","name":"Medtronic Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-026-00810-8","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:03:59Z","timestamp":1782799439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness and Budget Impact Analysis of Radiofrequency Renal Denervation for Uncontrolled and Resistant Hypertension in Italy"],"prefix":"10.1007","author":[{"given":"Flavio L.","family":"Ribichini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Ryschon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Pietzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"7","key":"810_CR1","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11739-023-03376-8","volume":"18","author":"S Romano","year":"2023","unstructured":"Romano S, Rigon G, Albrigi M, Tebaldi G, Sartorio A, Cristin L, et al. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. A population-based observational study. Intern Emerg Med. 2023;18(7):1951\u20139.","journal-title":"Intern Emerg Med"},{"issue":"38","key":"810_CR2","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"issue":"12","key":"810_CR3","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/hjh.0000000000003480.","journal-title":"J Hypertens"},{"issue":"15","key":"810_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","volume":"44","author":"E Barbato","year":"2023","unstructured":"Barbato E, Azizi M, Schmieder RE, Lauder L, B\u00f6hm M, Brouwers S, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44(15):1313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehad054.","journal-title":"Eur Heart J"},{"issue":"10","key":"810_CR5","first-page":"53","volume":"24","author":"E Stabile","year":"2023","unstructured":"Stabile E, Muiesan ML, Ribichini FL, Sangiorgi G, Taddei S, Versaci F, et al. Italian society of interventional cardiology (GISE) and Italian society of arterial hypertension (SIIA) consensus document on the role of renal denervation in the management of the difficult to treat hypertension. G Ital Cardiol (2006). 2023;24(10):53\u201363.","journal-title":"G Ital Cardiol (2006)."},{"issue":"8","key":"810_CR6","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s40620-025-02406-2","volume":"38","author":"S Feriozzi","year":"2025","unstructured":"Feriozzi S, Battaglia Y, Cirami CL, Gangemi C, La Manna G, Gesualdo L, et al. The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology. J Nephrol. 2025;38(8):2053\u201365. https:\/\/doi.org\/10.1007\/s40620-025-02406-2.","journal-title":"J Nephrol"},{"issue":"18","key":"810_CR7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567\u2013678. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.007.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"810_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40292-020-00367-0","volume":"27","author":"RM Bruno","year":"2020","unstructured":"Bruno RM, Taddei S, Borghi C, Colivicchi F, Desideri G, Grassi G, et al. Italian society of arterial hypertension (SIIA) position paper on the role of renal denervation in the management of the difficult-to-treat hypertensive patient. High Blood Press Cardiovasc Prev. 2020;27(2):109\u201317. https:\/\/doi.org\/10.1007\/s40292-020-00367-0.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"4","key":"810_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF03297936","volume":"19","author":"M Volpe","year":"2012","unstructured":"Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, et al. Renal artery denervation for treating resistant hypertension: definition of the disease, patient selection and description of the procedure. High Blood Press Cardiovasc Prev. 2012;19(4):237\u201344. https:\/\/doi.org\/10.1007\/BF03297936.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"19","key":"810_CR10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","volume":"82","author":"DE Kandzari","year":"2023","unstructured":"Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2023.08.045.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR11","doi-asserted-by":"publisher","first-page":"e015194","DOI":"10.1161\/CIRCINTERVENTIONS.125.015194","volume":"18","author":"DE Kandzari","year":"2025","unstructured":"Kandzari DE, Mahfoud F, Townsend RR, Kario K, Weber MA, Schmieder RE, et al. Long-term safety and efficacy of renal denervation: 24-month results from the SPYRAL HTN-ON MED trial. Circ Cardiovasc Interv. 2025;18:e015194.","journal-title":"Circ Cardiovasc Interv"},{"issue":"42","key":"810_CR12","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","volume":"40","author":"F Mahfoud","year":"2019","unstructured":"Mahfoud F, Boehm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474\u201382.","journal-title":"Eur Heart J"},{"issue":"6","key":"810_CR13","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1161\/HYPERTENSIONAHA.123.22314","volume":"81","author":"G Sesa-Ashton","year":"2024","unstructured":"Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Macefield VG, Dawood T, et al. Long-term blood pressure reductions following catheter-based renal denervation: a systematic review and meta-analysis. Hypertension. 2024;81(6):e63\u201370.","journal-title":"Hypertension"},{"issue":"3","key":"810_CR14","first-page":"101606","volume":"4","author":"F Mahfoud","year":"2025","unstructured":"Mahfoud F, Townsend RR, Kandzari DE, Mancia G, Whitbourn R, Lauder L, et al. Long-term, patient-level analysis of radiofrequency renal denervation in the SYMPLICITY clinical trial program. JACC: Adv. 2025;4(3):101606.","journal-title":"JACC: Adv."},{"key":"810_CR15","doi-asserted-by":"publisher","DOI":"10.4244\/eij-d-26-00161","author":"DE Kandzari","year":"2026","unstructured":"Kandzari DE, B\u00f6hm M, Schmieder RE, Townsend RR, Schlaich MP, Kario K, et al. Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL clinical program. EuroIntervention. 2026. https:\/\/doi.org\/10.4244\/eij-d-26-00161.","journal-title":"EuroIntervention"},{"issue":"8","key":"810_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ehjqcco\/qcae001","volume":"10","author":"ASP Sharp","year":"2024","unstructured":"Sharp ASP, Cao KN, Esler MD, Kandzari DE, Lobo MD, Schmieder RE, et al. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes. 2024;10(8):698\u2013708. https:\/\/doi.org\/10.1093\/ehjqcco\/qcae001.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"issue":"12","key":"810_CR17","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/jch.14922","volume":"26","author":"K Kario","year":"2024","unstructured":"Kario K, Cao KN, Tanaka Y, Ryschon AM, Pietzsch JB. Cost-effectiveness of radiofrequency renal denervation for uncontrolled hypertension in Japan. J Clin Hypertens. 2024;26(12):1502\u201312.","journal-title":"J Clin Hypertens"},{"issue":"10","key":"810_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2024.102234","volume":"3","author":"DE Kandzari","year":"2024","unstructured":"Kandzari DE, Cao KN, Ryschon AM, Sharp ASP, Pietzsch JB. Catheter-based radiofrequency renal denervation in the united states: a cost-effectiveness analysis based on contemporary evidence. J Soc Cardiovasc Angiogr Interv. 2024;3(10):102234. https:\/\/doi.org\/10.1016\/j.jscai.2024.102234.","journal-title":"J Soc Cardiovasc Angiogr Interv."},{"issue":"1","key":"810_CR19","doi-asserted-by":"publisher","first-page":"2573034","DOI":"10.1080\/08037051.2025.2573034","volume":"34","author":"J Daemen","year":"2025","unstructured":"Daemen J, Saville KA, Ryschon AM, Cao KN, van Kuijck J, Spiering W, et al. Cost-effectiveness of radiofrequency renal denervation for uncontrolled and resistant hypertension in The Netherlands. Blood Press. 2025;34(1):2573034. https:\/\/doi.org\/10.1080\/08037051.2025.2573034.","journal-title":"Blood Press"},{"issue":"1","key":"810_CR20","doi-asserted-by":"publisher","first-page":"2487583","DOI":"10.1080\/08037051.2025.2487583","volume":"34","author":"T Kahan","year":"2025","unstructured":"Kahan T, Johansen ML, Ryschon AM, Cao KN, Kolovetsios MD, Lindgren P, et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden. Blood Press. 2025;34(1):2487583.","journal-title":"Blood Press"},{"issue":"4","key":"810_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.24875\/RECICE.M24000475","volume":"6","author":"O Rodr\u00edguez-Leor","year":"2024","unstructured":"Rodr\u00edguez-Leor O, Ryschon AM, Cao KN, Ja\u00e9n-\u00c1guila F, Garc\u00eda-Camarero T, Mansilla-Morales C, et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain. REC Interv Cardiol. 2024;6(4):305\u201312. https:\/\/doi.org\/10.24875\/RECICE.M24000475.","journal-title":"REC Interv Cardiol."},{"issue":"5","key":"810_CR22","first-page":"1","volume":"14","author":"F Fiorentino","year":"2021","unstructured":"Fiorentino F, Urbinati D. First Italian guidelines for the economic evaluation of health technologies: how do they compare to NICE standards. GIHTAD. 2021;14(5):1\u20136.","journal-title":"GIHTAD."},{"key":"810_CR23","doi-asserted-by":"crossref","unstructured":"Capri S, Ceci A, Terranova L, Merlo F, Mantovani L, Studies MotIGfP. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J. 2001;35:189\u2013201.","DOI":"10.1177\/009286150103500122"},{"issue":"14","key":"810_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","volume":"60","author":"BP Geisler","year":"2012","unstructured":"Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"810_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","volume":"139","author":"RB D'Agostino","year":"2000","unstructured":"D\u2019Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2):272\u201381.","journal-title":"Am Heart J"},{"issue":"1","key":"810_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/01.STR.25.1.40","volume":"25","author":"RB D'Agostino","year":"1994","unstructured":"D\u2019Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study Stroke. 1994;25(1):40\u20133.","journal-title":"The Framingham Study. Stroke."},{"issue":"6","key":"810_CR27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/ije\/31.6.1253","volume":"31","author":"R Voss","year":"2002","unstructured":"Voss R, Cullen P, Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular M\u00fcnster Study (PROCAM) using neural networks. Inter JEpidemiol. 2002;31(6):1253\u201362.","journal-title":"Inter JEpidemiol."},{"issue":"20","key":"810_CR28","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1161\/CIRCULATIONAHA.108.784215","volume":"118","author":"RS Velagaleti","year":"2008","unstructured":"Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D\u2019Agostino RB, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057\u201362.","journal-title":"Circulation"},{"issue":"12","key":"810_CR29","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","volume":"32","author":"C Thomopoulos","year":"2014","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285\u201395.","journal-title":"J Hypertens"},{"issue":"8","key":"810_CR30","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1161\/STROKEAHA.107.510362","volume":"39","author":"G Saposnik","year":"2008","unstructured":"Saposnik G, Hill MD, O\u2019Donnell M, Fang J, Hachinski V, Kapral MK. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke. 2008;39(8):2318\u201324.","journal-title":"Stroke"},{"issue":"5","key":"810_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jstrokecerebrovasdis.2005.06.002","volume":"14","author":"MN Andersen","year":"2005","unstructured":"Andersen MN, Andersen KK, Kammersgaard LP, Olsen TS. Sex differences in stroke survival: 10-year follow-up of the Copenhagen stroke study cohort. J Stroke and Cerebrovasc Dis. 2005;14(5):215\u201320.","journal-title":"J Stroke and Cerebrovasc Dis."},{"issue":"3","key":"810_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, D\u2019Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312\u20138.","journal-title":"Stroke"},{"key":"810_CR33","unstructured":"Institute of National Statistics. Mortality 2024. Accessed 18 April 2025. Available from: http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_MORTALITA1&Lang=en."},{"key":"810_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144560","author":"L De Luca","year":"2023","unstructured":"De Luca L, D\u2019Errigo P, Rosato S, Badoni G, Giordani B, Mureddu GF, et al. Impact of COVID-19 diagnosis on mortality in patients with ischemic stroke admitted during the 2020 pandemic in Italy. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12144560.","journal-title":"J Clin Med"},{"issue":"5","key":"810_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.healthpol.2019.01.010","volume":"123","author":"C Seghieri","year":"2019","unstructured":"Seghieri C, Berta P, Nuti S. Geographic variation in inpatient costs for acute myocardial infarction care: insights from Italy. Health Policy. 2019;123(5):449\u201356.","journal-title":"Health Policy"},{"issue":"4","key":"810_CR36","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/circoutcomes.111.964700","volume":"5","author":"K Smolina","year":"2012","unstructured":"Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5(4):532\u201340. https:\/\/doi.org\/10.1161\/circoutcomes.111.964700.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"810_CR37","doi-asserted-by":"publisher","first-page":"b3058","DOI":"10.1136\/bmj.b3058","volume":"339","author":"BS Buckley","year":"2009","unstructured":"Buckley BS, Simpson CR, McLernon DJ, Murphy AW, Hannaford PC. Five year prognosis in patients with angina identified in primary care: incident cohort study. BMJ. 2009;339:b3058.","journal-title":"BMJ"},{"issue":"8","key":"810_CR38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jchf.2019.04.023","volume":"7","author":"RS Taylor","year":"2019","unstructured":"Taylor RS, Long L, Mordi IR, Madsen MT, Davies EJ, Dalal H, et al. Exercise-based rehabilitation for heart failure: Cochrane systematic review, meta-analysis, and trial sequential analysis. JACC Heart Fail. 2019;7(8):691\u2013705.","journal-title":"JACC Heart Fail."},{"issue":"8","key":"810_CR39","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/ckj\/sfad087","volume":"16","author":"ME Astley","year":"2023","unstructured":"Astley ME, Boenink R, Abd ElHafeez S, Trujillo-Alem\u00e1n S, Arribas F, \u00c5sberg A, et al. The ERA registry annual report 2020: a summary. ClinKidney J. 2023;16(8):1330\u201354. https:\/\/doi.org\/10.1093\/ckj\/sfad087.","journal-title":"ClinKidney J."},{"key":"810_CR40","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S2254441961-1969","author":"D Putignano","year":"2019","unstructured":"Putignano D, Orlando V, Monetti VM, Piccinocchi G, Musazzi UM, Piccinocchi R, et al. Fixed versus free combinations of antihypertensive drugs: analyses of real-world data of persistence with therapy in Italy. Patient Pref Adher. 2019. https:\/\/doi.org\/10.2147\/PPA.S2254441961-1969.","journal-title":"Patient Pref Adher."},{"key":"810_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-12-137","volume":"12","author":"G Fattore","year":"2012","unstructured":"Fattore G, Torbica A, Susi A, Giovanni A, Benelli G, Gozzo M, et al. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study. BMC Neurol. 2012;12:1\u201311.","journal-title":"BMC Neurol"},{"key":"810_CR42","doi-asserted-by":"publisher","first-page":"1307534","DOI":"10.3389\/fcvm.2024.1307534","volume":"11","author":"A Fortunato","year":"2024","unstructured":"Fortunato A, Valentini I, Rumi F, Antonini D, Siviero L, Di Brino E, et al. A budget impact model and a cost\u2013utility analysis of reducer device (Neovasc) in patients with refractory angina. Front Cardiovasc Med. 2024;11:1307534.","journal-title":"Front Cardiovasc Med."},{"key":"810_CR43","unstructured":"Italian Ministry of Health. Decreto 18 Ottobre 2012: Gazzetta Ufficiale 2013. Accessed 18 April 2025. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2013\/01\/28\/13A00528\/sg."},{"key":"810_CR44","first-page":"94","volume":"11","author":"M Dovizio","year":"2024","unstructured":"Dovizio M, Leogrande M, Degli EL. Scompenso cardiaco e impatto economico: un\u2019analisi nella reale pratica clinica in Italia. GlobReg Health Technol Assess. 2024;11:94.","journal-title":"GlobReg Health Technol Assess."},{"issue":"11","key":"810_CR45","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.34067\/KID.0007462021","volume":"3","author":"A Pani","year":"2022","unstructured":"Pani A, Capasso G. Global dialysis perspective: Italy. Kidney360. 2022;3(11):1948\u201352.","journal-title":"Kidney360"},{"key":"810_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-020-1689-z","volume":"21","author":"C Marino","year":"2020","unstructured":"Marino C, Ferraro PM, Bargagli M, Cascini S, Agabiti N, Gambaro G, et al. Prevalence of chronic kidney disease in the Lazio region, Italy: a classification algorithm based on health information systems. BMC Nephrol. 2020;21:1\u201310.","journal-title":"BMC Nephrol"},{"issue":"14","key":"810_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11140","volume":"11","author":"S Ward","year":"2007","unstructured":"Ward S, Jones ML, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1\u2013160. https:\/\/doi.org\/10.3310\/hta11140.","journal-title":"Health Technol Assess"},{"key":"810_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF03320529","volume":"12","author":"T Paletta","year":"2010","unstructured":"Paletta T, Lucioni C, Volpe M. EuroQol (EQ-5D) as a utility measure in patients with myocardial infarction: Considerazioni metodologiche applicate al caso del paziente in dimissione dopo infarto miocardico. PharmacoEcon Ital Res Artic. 2010;12:51\u20139.","journal-title":"PharmacoEcon Ital Res Artic."},{"issue":"7","key":"810_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199770","volume":"13","author":"L De Luca","year":"2018","unstructured":"De Luca L, Temporelli PL, Lucci D, Colivicchi F, Calabr\u00f2 P, Riccio C, et al. Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: insights from the START study. PLoS ONE. 2018;13(7):e0199770. https:\/\/doi.org\/10.1371\/journal.pone.0199770.","journal-title":"PLoS ONE"},{"issue":"1","key":"810_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/eurheartj\/ehr504","volume":"34","author":"J Comin-Colet","year":"2013","unstructured":"Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, L\u00fcscher TF, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J. 2013;34(1):30\u20138.","journal-title":"Eur Heart J"},{"issue":"6","key":"810_CR51","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","volume":"68","author":"I Gorodetskaya","year":"2005","unstructured":"Gorodetskaya I, Zenios S, Mcculloch CE, Bostrom A, Hsu C-Y, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801\u20138.","journal-title":"Kidney Int"},{"issue":"21","key":"810_CR52","doi-asserted-by":"publisher","first-page":"e1288","DOI":"10.4244\/eij-d-25-00217","volume":"21","author":"V Galli","year":"2025","unstructured":"Galli V, Galuppi E, Tavella D, Gangemi C, Gambaro A, Casal M, et al. Long-term effects of radiofrequency-based renal denervation on blood pressure and renal function by degree of renal dysfunction. EuroIntervention. 2025;21(21):e1288\u201390. https:\/\/doi.org\/10.4244\/eij-d-25-00217.","journal-title":"EuroIntervention"},{"key":"810_CR53","unstructured":"Italian National Institute of Statistics. Consumer prices for the whole nation (Nic) 2025. Accessed 9 September 2025. Available from: https:\/\/esploradati.istat.it\/databrowser\/#\/en\/dw\/categories\/IT1,Z0400PRI,1.0\/PRI_CONWHONAT."},{"issue":"1","key":"810_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40273-022-01215-w","volume":"41","author":"P Russo","year":"2023","unstructured":"Russo P, Zanuzzi M, Carletto A, Sammarco A, Romano F, Manca A. Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023;41(1):107\u201317.","journal-title":"Pharmacoeconomics"},{"key":"810_CR55","unstructured":"Dymedex. The Disease Dynamics Series - Hypertension and Resistant Hypertension 2015. Accessed 9 September 2025. Available from: http:\/\/www.dymedex.com\/reports."},{"key":"810_CR56","doi-asserted-by":"publisher","unstructured":"Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957\u2013980. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1.","DOI":"10.1016\/S0140-6736(21)01330-1"},{"issue":"5","key":"810_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2015.10.037","volume":"67","author":"AP Bress","year":"2016","unstructured":"Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT results to the US adult population. J Am Coll Cardiol. 2016;67(5):463\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"810_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11906-022-01173-w","volume":"24","author":"LCC Brant","year":"2022","unstructured":"Brant LCC, Passaglia LG, Pinto-Filho MM, de Castilho FM, Ribeiro ALP, Nascimento BR. The burden of resistant hypertension across the world. Curr Hypertens Rep. 2022;24(3):55\u201366.","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"810_CR59","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00392-019-01468-0","volume":"108","author":"RE Schmieder","year":"2019","unstructured":"Schmieder RE, H\u00f6gerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12):1331\u201342.","journal-title":"Clin Res Cardiol"},{"key":"810_CR60","unstructured":"OECD. Healthcare Coverage 2025. Accessed 9 September 2025. Available from: https:\/\/data-explorer.oecd.org\/."},{"key":"810_CR61","unstructured":"Institute of National Statistics. Resident population, by sex, age and marital status as of 1 January 2025. 2025. Accessed 9 September 2025. Available from: https:\/\/demo.istat.it\/."},{"issue":"Suppl B","key":"810_CR62","doi-asserted-by":"publisher","first-page":"B77","DOI":"10.1093\/eurheartj\/suab054","volume":"23","author":"C Torlasco","year":"2021","unstructured":"Torlasco C, Faini A, Pengo MF, Borghi C, Grassi G, Ferri C, et al. May Measurement Month 2019: an analysis of blood pressure screening results from Italy. Eur Heart J Suppl. 2021;23(Suppl B):B77-b81. https:\/\/doi.org\/10.1093\/eurheartj\/suab054.","journal-title":"Eur Heart J Suppl."},{"issue":"15","key":"810_CR63","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1111\/bph.70063","volume":"182","author":"F Pu","year":"2025","unstructured":"Pu F, Liu Y, Ahmed FZ, Wang X, Green D, Zhang H. Advancing antihypertensive drug development. Br J Pharmacol. 2025;182(15):3389\u2013410.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"810_CR64","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/biomedicines13040790","volume":"13","author":"F Schinzari","year":"2025","unstructured":"Schinzari F, Montenero R, Cardillo C, Tesauro M. Emerging pharmacological approaches for the treatment of arterial hypertension. Biomedicines. 2025;13(4):790.","journal-title":"Biomedicines."},{"issue":"4","key":"810_CR65","doi-asserted-by":"publisher","first-page":"27963","DOI":"10.31083\/RCM27963","volume":"26","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Zhai C, Tang G. Novel antihypertensive medications to target the renin-angiotensin system: mechanisms and research. Rev CardiovascMed. 2025;26(4):27963.","journal-title":"Rev CardiovascMed."},{"issue":"5","key":"810_CR66","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C, Fernandez Fernandez B, Ghali JK, Kopjar B, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA. 2025;334(5):409\u201318.","journal-title":"JAMA"},{"issue":"Supplement_5","key":"810_CR67","doi-asserted-by":"publisher","first-page":"v177","DOI":"10.1093\/eurheartjsupp\/suag049","volume":"28","author":"G Gallo","year":"2026","unstructured":"Gallo G, Volterrani M, Tocci G, Volpe M. Aldosterone synthesis inhibitors in resistant hypertension: the BaxHTN trial. Eur Heart J Suppl. 2026;28(Supplement_5):v177\u201380.","journal-title":"Eur Heart J Suppl."}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00810-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-026-00810-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00810-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:15:23Z","timestamp":1782850523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-026-00810-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":67,"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s40292-026-00810-8","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FLR and ST report consulting fees from Medtronic; AMR, SAW, and JBP report consulting fees from Medtronic received through their employer, Wing Tech Inc.; ET is an employee of Medtronic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This was a post hoc analysis of published clinical data and as a result does not report directly on patient-level data. No IRB approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This analysis was conducted in accordance with CHEERS guidelines for economic evaluations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standards of Reporting"}}]}}